Skip to main content
Top
Published in: Journal of Gastroenterology 9/2013

01-09-2013 | Original Article—Alimentary Tract

Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study

Authors: Aki Kawakami, Makoto Tanaka, Masakazu Nishigaki, Makoto Naganuma, Yasushi Iwao, Toshifumi Hibi, Hiromi Sanada, Noriko Yamamoto-Mitani, Keiko Kazuma

Published in: Journal of Gastroenterology | Issue 9/2013

Login to get access

Abstract

Background

Thirty to forty-five percent of ulcerative colitis (UC) patients show non-adherence to aminosalicylates, and non-adherence has been reported to increase the risk of clinical relapse. Because Japan differs from Western countries in terms of health care and drugs administered, adherence to aminosalicylates in Japan may differ from that elsewhere. Therefore, we examined aminosalicylate adherence and its relationship to the risk of clinical relapse of UC in Japan.

Methods

A 1-year, prospective cohort study was conducted in 104 outpatients with UC in remission who had taken aminosalicylates >6 months. Aminosalicylate adherence was evaluated using data from a self-administered questionnaire and medical records. Non-adherence was defined as taking <80 % of the prescribed dose of aminosalicylates. The primary outcome was the record of clinical relapse in medical charts.

Results

Twenty-nine patients (27.9 %) were evaluated as showing non-adherence. Among all subjects, 24 patients (23.1 %) relapsed. The non-adherence group had a higher rate of 1-year relapse than did the adherence group (41.3 vs. 16.0 %). Multiple Cox regression analysis showed that non-adherence increased the risk of clinical relapse 2.3-fold (hazard ratio 2.3, 95 % confidence interval 1.004–5.24, p = 0.04).

Conclusions

Although the adherence rate in this study was slightly higher than that in previous studies, Japanese patients with UC who were not adherent to their medications had a twofold greater risk of relapse than those who were. These results indicate the importance of early identification of patients with non-adherence. A program to support medication taking behavior is needed to prevent UC relapse.
Literature
1.
go back to reference Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57.PubMedCrossRef Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57.PubMedCrossRef
2.
go back to reference Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009;44:659–65.PubMedCrossRef Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009;44:659–65.PubMedCrossRef
3.
go back to reference Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRef Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRef
4.
go back to reference Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453–68.PubMedCrossRef Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453–68.PubMedCrossRef
5.
go back to reference Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–40.PubMedCrossRef Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–40.PubMedCrossRef
6.
go back to reference Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:601–16.PubMedCrossRef Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:601–16.PubMedCrossRef
7.
go back to reference Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.PubMedCrossRef Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.PubMedCrossRef
8.
go back to reference Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345–53.PubMedCrossRef Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345–53.PubMedCrossRef
9.
go back to reference van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573–8.PubMedCrossRef van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573–8.PubMedCrossRef
10.
go back to reference Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105:525–39.PubMedCrossRef Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105:525–39.PubMedCrossRef
11.
go back to reference Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39–43.PubMedCrossRef Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39–43.PubMedCrossRef
12.
go back to reference Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2008;4:1–25. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2008;4:1–25.
13.
go back to reference Cooney R, Warren B, Altman D, Abreu M, Travis S. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials. 2007;8:1.CrossRef Cooney R, Warren B, Altman D, Abreu M, Travis S. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials. 2007;8:1.CrossRef
14.
go back to reference Travis S, Higgins P, Orchard T, Van der Woude C, Panaccione R, Bitton A, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;34:113–24.PubMedCrossRef Travis S, Higgins P, Orchard T, Van der Woude C, Panaccione R, Bitton A, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;34:113–24.PubMedCrossRef
15.
go back to reference Bello C, Belaiche J, Louis E, Reenaers C. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011;5:196–202.PubMedCrossRef Bello C, Belaiche J, Louis E, Reenaers C. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011;5:196–202.PubMedCrossRef
16.
go back to reference Romberg-Camps M, Dagnelie P, Kester AD, Hesselink-van de Kruijs M, Cilissen M, Engels L, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104:371–83.PubMedCrossRef Romberg-Camps M, Dagnelie P, Kester AD, Hesselink-van de Kruijs M, Cilissen M, Engels L, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104:371–83.PubMedCrossRef
17.
go back to reference Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.PubMedCrossRef Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.PubMedCrossRef
18.
go back to reference Hoie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102:1692–701.PubMedCrossRef Hoie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102:1692–701.PubMedCrossRef
19.
go back to reference Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.PubMedCrossRef Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.PubMedCrossRef
21.
go back to reference Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics. 2010;28:1097–107.PubMedCrossRef Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics. 2010;28:1097–107.PubMedCrossRef
22.
go back to reference Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.PubMedCrossRef Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.PubMedCrossRef
23.
go back to reference Higashi A, Yashiro H, Kiyota K, Inokuchi H, Hatta H, Fujita K, et al. Validation of the hospital anxiety and depression scale in a gastro-intestinal clinic (in Japanese with English abstract). Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol). 1996;93:18–26. Higashi A, Yashiro H, Kiyota K, Inokuchi H, Hatta H, Fujita K, et al. Validation of the hospital anxiety and depression scale in a gastro-intestinal clinic (in Japanese with English abstract). Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol). 1996;93:18–26.
24.
go back to reference Yamamoto T, Hashimoto M. Reliability and validity of a Japanese version of the trust in physician scale (in Japanese with English abstract). Nippon Iryo Byoin Kanri Gakkaishi (J Jpn Soc Healthc Adm). 2008;45:227–35. Yamamoto T, Hashimoto M. Reliability and validity of a Japanese version of the trust in physician scale (in Japanese with English abstract). Nippon Iryo Byoin Kanri Gakkaishi (J Jpn Soc Healthc Adm). 2008;45:227–35.
25.
go back to reference Anderson LA, Dedrick RF. Development of the Trust in Physician scale: a measure to assess interpersonal trust in patient–physician relationships. Psychol Rep. 1990;67:1091–100.PubMed Anderson LA, Dedrick RF. Development of the Trust in Physician scale: a measure to assess interpersonal trust in patient–physician relationships. Psychol Rep. 1990;67:1091–100.PubMed
26.
go back to reference Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis—a 6-month placebo-controlled trial. Aliment Pharmacol Ther. 2010;32:990–9.PubMedCrossRef Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis—a 6-month placebo-controlled trial. Aliment Pharmacol Ther. 2010;32:990–9.PubMedCrossRef
27.
go back to reference Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13–20.PubMedCrossRef Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13–20.PubMedCrossRef
28.
go back to reference Nieuwkerk PT, de Boer-van der Kolk IM, Prins JM, Locadia M, Sprangers MAG. Self-reported adherence is more predictive of virological treatment response among patients with a lower tendency towards socially desirable responding. Antivir Ther. 2010;15:913–6.PubMedCrossRef Nieuwkerk PT, de Boer-van der Kolk IM, Prins JM, Locadia M, Sprangers MAG. Self-reported adherence is more predictive of virological treatment response among patients with a lower tendency towards socially desirable responding. Antivir Ther. 2010;15:913–6.PubMedCrossRef
29.
go back to reference Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:630–42.PubMedCrossRef Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:630–42.PubMedCrossRef
30.
go back to reference Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535–44.PubMedCrossRef Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535–44.PubMedCrossRef
31.
go back to reference Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929–33.PubMedCrossRef Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929–33.PubMedCrossRef
32.
go back to reference Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1417–26.PubMedCrossRef Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1417–26.PubMedCrossRef
33.
go back to reference Kawakami A, Tanaka M, Ochiai R, Naganuma M, Iwao Y, Hibi T, et al. Difficulties in taking aminosalicylates for patients with ulcerative colitis. Gastroenterol Nurs. 2012;35:24–31.PubMedCrossRef Kawakami A, Tanaka M, Ochiai R, Naganuma M, Iwao Y, Hibi T, et al. Difficulties in taking aminosalicylates for patients with ulcerative colitis. Gastroenterol Nurs. 2012;35:24–31.PubMedCrossRef
34.
go back to reference Asai A, Kishino M, Tsuguya F, Sakai M, Yokota M, Nakata K, et al. A report from Japan: choices of Japanese patients in the face of disagreement. Bioethics. 1998;12:162–72.PubMedCrossRef Asai A, Kishino M, Tsuguya F, Sakai M, Yokota M, Nakata K, et al. A report from Japan: choices of Japanese patients in the face of disagreement. Bioethics. 1998;12:162–72.PubMedCrossRef
35.
go back to reference Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2–25.PubMedCrossRef Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2–25.PubMedCrossRef
36.
go back to reference Leffler D, Cheifetz A. Forecasting the recurrence of ulcerative colitis: can U.C. the future? Inflamm Bowel Dis. 2009;14:422–4.CrossRef Leffler D, Cheifetz A. Forecasting the recurrence of ulcerative colitis: can U.C. the future? Inflamm Bowel Dis. 2009;14:422–4.CrossRef
37.
go back to reference Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004;53:1479–84.PubMedCrossRef Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004;53:1479–84.PubMedCrossRef
38.
go back to reference Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR, et al. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr. 2004;23:161–70.PubMedCrossRef Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR, et al. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr. 2004;23:161–70.PubMedCrossRef
39.
go back to reference Bitton A, Sewitch M, Peppercorn M, deB Edwardes M, Shah S, Ransil B, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol. 2003;98:2203–8.PubMedCrossRef Bitton A, Sewitch M, Peppercorn M, deB Edwardes M, Shah S, Ransil B, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol. 2003;98:2203–8.PubMedCrossRef
40.
go back to reference Fujimoto T, Kato J, Nasu J, Kuriyama M, Okada H, Yamamoto H, et al. Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981 to 2000. Eur J Gastroenterol. 2007;19:229–35.CrossRef Fujimoto T, Kato J, Nasu J, Kuriyama M, Okada H, Yamamoto H, et al. Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981 to 2000. Eur J Gastroenterol. 2007;19:229–35.CrossRef
41.
go back to reference Kuwahara E, Asakura K, Nishiwaki Y, Inoue N, Watanabe M, Hibi T, et al. Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol. 2012 [Epub ahead of print]. Kuwahara E, Asakura K, Nishiwaki Y, Inoue N, Watanabe M, Hibi T, et al. Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol. 2012 [Epub ahead of print].
42.
go back to reference Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1–23.PubMedCrossRef Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1–23.PubMedCrossRef
Metadata
Title
Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study
Authors
Aki Kawakami
Makoto Tanaka
Masakazu Nishigaki
Makoto Naganuma
Yasushi Iwao
Toshifumi Hibi
Hiromi Sanada
Noriko Yamamoto-Mitani
Keiko Kazuma
Publication date
01-09-2013
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 9/2013
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0721-x

Other articles of this Issue 9/2013

Journal of Gastroenterology 9/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.